BioCryst Pharmaceuticals
BCRX
318 hedge funds and large institutions have $2.61B invested in BioCryst Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 56 funds opening new positions, 132 increasing their positions, 88 reducing their positions, and 37 closing their positions.
315% more call options, than puts
Call options by funds: $31.5M | Put options by funds: $7.59M
51% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 37
50% more repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 88
10% more capital invested
Capital invested by funds: $2.37B → $2.61B (+$242M)
5% more funds holding
Funds holding: 302 → 318 (+16)
3.53% more ownership
Funds ownership: 99.39% → 102.92% (+3.5%)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$29M |
| 2 |
State Street
Boston,
Massachusetts
|
+$27M |
| 3 |
PA
Perceptive Advisors
New York
|
+$26M |
| 4 |
Jane Street
New York
|
+$19.4M |
| 5 |
Goldman Sachs
New York
|
+$19.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RPSM
Royalty Pharma Sub-Manager
New York
|
-$36.6M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$28.6M |
| 3 |
RA
RFG Advisory
Birmingham,
Alabama
|
-$27.3M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14.6M |
| 5 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$14.1M |
BCRX Hedge Fund Activity: Q2 2026 in Review
318 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2026, worth a combined $2.61B — up 10% from $2.37B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new BCRX positions and 37 closed out — a net gain of 19 holders — while 132 added to existing stakes and 88 trimmed.
The largest buyer was Millennium Management, adding an estimated $29M. The largest seller was Royalty Pharma Sub-Manager, exiting entirely with an estimated $36.6M sold.
- 318 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2026, up from 302 in Q1 2026.
- Funds reported $2.61B of BioCryst Pharmaceuticals stock for Q2 2026, up 10% quarter-over-quarter.
- 56 funds opened new BioCryst Pharmaceuticals positions in Q2 2026 and 37 closed out, a net change of +19 holders.
- The largest BioCryst Pharmaceuticals buyer in Q2 2026 was Millennium Management, an estimated $29M added.
- The largest BioCryst Pharmaceuticals seller in Q2 2026 was Royalty Pharma Sub-Manager, an estimated $36.6M sold.
Based on aggregated 13F filings for Q2 2026.